Going out to detect incipient diabetic nephropathy rather than waiting until it has supervened-a reversal in policy H.-H. Parving Steno Diabetes Center, Gentofte, Denmark Persistent albuminuria (>300 mg/24 h or 200 ug/min) is the hallmark of diabetic nephropathy, which can be diagnosed clinically if the following additional criteria are fulfilled: presence of diabetic retinopathy and no clinical or laboratory evidence of kidney or urinary tract disease other than diabetic glomerulosclerosis [1] . This clinical definition of diabetic nephropathy is valid both in insulin dependent diabetic (IDDM) and noninsulin dependent diabetic (NIDDM) patients. Albuminuric NIDDM patients without retinopathy require further evaluation, that is, kidney biopsy, since the chances for diabetic and non-diabetic glomerulopathy are approximately fifty-fifty [2] . The clinical syndrome termed diabetic nephropathy is characterized by persistent albuminuria, early blood pressure elevation, a relentless decline in GFR, and high risk of cardiovascular morbidity and mortality. Diabetic nephropathy has become a leading cause of end-stage renal disease (ESRD) in the world. Both IDDM and NIDDM patients contribute to the increase in ESRD. Prevention of diabetic nephropathy, or at least the postponement or slowing down of the disease process has emerged as a key issue. In the past years six sets of recommendations on the prevention of diabetic nephropathy, with special reference to microalbuminuria, have been published, as reviewed by Mogensen et al. [3] . Since the six programs proposed differ, an agreed unifying, global strategy for screening and treatment of diabetic patients with persistent microalbuminuria has been advocated [3] . This report focuses on microalbuminuria because this is the first clinical sign of risk of diabetic nephropathy and other vascular complications and prevention is best achieved at this early stage.
Microalbuminuria

Detection, monitoring
Microalbuminuria is defined as a urinary albumin excretion (UAE) rate of 30-300 mg/24 h or 20-200 ug/min. If UAE in two out of three consecutive timed urine collections are within the above mentioned range the term persistent microalbuminuria or incipient diabetic nephropathy is commonly used. Several procedures for urine sampling have been proposed: 24 h
Correspondence and offprint requests to: Hans-Henrik Parving. Steno Diabetes Center. Niels Steensens Vej 2, DK-2820 Gentofte. Denmark. urine collection, overnight collection, short-term collection in the clinic, and urinary albumin-creatinine ratio in random or early morning (first voided) urine. An urinary albumin/creatinine ratio of 30-300 mg/g or 2.5-25 mg/mmol are suggestive of microalbuminuria. The ratio can be used for screening and also for monitoring of the treatment, but confirmatory tests are best performed by use of timed urine collections. Urinary albumin excretion can vary by as much as 40% due to natural fluctuation so several tests should be done. Inexpensive RIA, ELISA, or immunoturbidimetric assays are now routine in many clinical laboratories.
There are several confounding factors for microalbuminuria such as hypertension, massive obesity, heavy exercise, urinary tract infection, various acute and chronic illnesses, cardiac failure, and use of various drugs e.g. NSAID (reduces microalbuminuria).
Epidemiology
The prevalence of microalbuminuria various between 8-30% with a median value of 15-20% in both IDDM and NIDDM patients measured in the clinic or in population based studies [1] . Microalbuminuria has been identified as the strongest predictor of diabetic nephropathy and approximately 80-90% of patients with persistent microalbuminuria will eventually progress to overt diabetic nephropathy. The rate of progression is slower in patients with late onset microalbuminuria. Several studies have demonstrated that microalbuminuria independently predicts neuropathy, retinopathy, foot ulcers, dyslipidemia, cardiovascular morbidity, and all causes of mortality in diabetes mellitus [1] . Microalbuminuria also predicts coronary and peripheral vascular disease and death from cardiovascular disease in the non-diabetic population.
Prevention and intervention in diabetes
The two major treatment modalities available are blood glucose control and control of blood pressure particularly with ACE inhibitors.
All long-term randomized trials have documented a beneficial impact on the rate of rise in UAE and in the development of overt nephropathy in IDDM patients with persistent microalbuminuria as reviewed by Wang [4] . The odds ratio for progressing from microalbuminuria to overt nephropathy range from 0.3 to 0.6 in the groups receiving intensified treatment. The Diabetes Control and Complications Trial (DCCT) Research Group [5] have confirmed and extended the above mentioned information by clearly documenting that good blood glucose control will postpone or prevent microalbuminuria and overt diabetic nephropathy. The risk reduction was approximately 50%. Recently, a 5-year randomized trial comparing conventional and multiple insulin injection treatment in NIDDM patients with and without microalbuminuria [6] has revealed the same beneficial effect as found in the DCCT study. The above mentioned studies suggest that good blood glucose control (HbA lc below 7.5-8.0%) in diabetic patients will preserve renal function and prevent development of microalbuminuria. In addition to weight gain the most serious complication to intensified insulin treatment is severe hypoglycaemic attacks which occur at a rate at least three times higher than in the conventional insulin treated IDDM patient. Frequent daily measurement of blood glucose is required in order to achieve good metabolic control.
For hypertensive diabetic patients with microalbuminuria all recommendations stressed tight control of blood pressure [3] . ACE inhibitors are usually preferred because their effect on albuminuria may to some extend be independent of their effect on systemic blood pressure. Target goal for blood pressure below 120-130/80-85 mm Hg, especially in young patients. It is suggested that antihypertensive regimes should be tailored individually. Hypertensive diabetic patients with microalbuminuria frequently have sodium retention and even oedema, requiring prescription of diuretic agents.
During the last decade several randomized, parallel studies comparing ACE inhibitors with placebo have been conducted in normotensive microalbuminuric IDDM patients [7] [8] [9] . All the long term studies (> 1 year) have shown a beneficial effect of ACE inhibition in postponing the development of overt nephropathy. Furthermore, a recent 8-year prospective study has documented that the beneficial effect of ACE inhibition is long lasting. Cough was the most frequently recorded but no patients were withdrawn due to side-effects in the above mentioned trials. Borch-Johnsen et al. [10] conducted a cost-benefit analysis of screening and antihypertensive treatment (mainly ACE-inhibition) of early renal disease indicated by microalbuminuria in IDDM patients. The authors concluded that screening and intervention programs are likely to have life-saving effects and lead to considerable economic savings.
The impact of ACE-inhibition in normotensive microalbuminuric NIDDM patients has also been evaluated. Ravid et al. [11] conducted a double blind randomized study in 94 normotensive microalbuminuric NIDDM patients receiving enalapril or placebo for 5 years. In the actively treated group the kidney function remained stable and diabetic nephropathy developed in only 12% of the patients. However, in the group receiving placebo, nephropathy developed in 42% of the patients and kidney function declined 1729 by 13%. A recent 7-year follow up of the trial confirmed the original data.
Monitoring of microalbuminuria, blood pressure, and kidney function should be conducted regularly at clinic visits. The treatment goals are: stable or declining microalbuminuria, stable kidney function (GFR), blood pressure 120-130/80-85 mm Hg and haemoglobin A lc below 7.5-8%.
In conclusion, screening for microalbuminuria should be performed yearly in all adult diabetic patients below the age of 70 years, abnormal screening values should be confirmed by timed urine collections taking into account the high day to day variability and various confounding variables. If persistent diabetic microalbuminuria is confirmed, improved blood glucose control and treatment with ACE inhibition should be initiated in an attempt to stabilize or even reduce microalbuminuria, preserve kidney function and thus postpone diabetic nephropathy and ESRD. A new concept is 'antihypertensive treatment' or renal protective treatment, even when the blood pressure is not at conventional hypertensive levels. The program outlined here is very cost-effective [10] , mainly because ESRD treatment is so expensive
